Système cardiovasculaire - MedQual

139. Douketis J et al. Low-molecular-weight heparin as bridging anticoagulation during interruption of
warfarin. Arch Intern Med 2004;164:1319-1326.
140. The Atrial Fibrillation Follow-up Investigation of Rythm Management (AFFIRM) Investigators. A
comparison of rate control and rythm control in patients with atrial fibrillation. N Engl J Med
2002;347:1825-33.
141. Van Gelder I, Hagens V, Bosker H et al, for the rate control versus electrical cardioversion for persistent
atrial fibrillation study group. N Engl J Med 2002;347:1834-40.
142. De Denus S, Sanoski C, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation. A metaanalysis.
Arch Intern Med 2005;165:258-262.
143. Fuster V, Ryden L, Asinger R et al, American College of Cardiology/American Heart
Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of
patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology
Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the
Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American
Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
144. Farshi R, Kistner D, Sarma J et al. Ventricular rate control in chronic atrial fibrillation during daily activity
and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol
1999;33:304-10.
145. Boos J, Lane D, Lip G. Atrial fibrillation (chronic). Clinical Evidence [online] 2007 [cited Dec 2007].
www.clinicalevidence.com
146. Boode BSP, Frijling BD, Heeringa J, Rutten FH, Van den Berg PJ, Zwietering PJ, Romeijnders ACM, Van
Lieshout J. NHG-Standaard Atriumfibrilleren. Huisarts Wet 2003;46:819-30. http://nhg.artsennet.nl.
147. New Zealand Guidelines Group. The management of people with atrial fibrillation and flutter. May
2005. www.nzgg.org.nz
148. Hollander M et al. Incidence, risk, and case fatality of first ever stroke in the elderly population. The
Rotterdam Study. J Neurol Neurosurg Psychiatry 2003;74:317-321.
149. Anonymous. Dipyridamol/acetylsalicylzuur. Geneesmiddelenbulletin 1999;33:19-20.
150. Sacco R, Adams R, Albers G et al. Guidelines for the prevention of stroke in patients with ischemic
stroke or transient ischemic attack. Circulation 2006;113:e409-e449.
151. Rashid P et al. Blood pressure reduction and secondary prevention of stroke and other vascular events. A
systematic review. Stroke 2003;34:2741-2749.
152. Anonymous. Clopidogrel (Iscover, Plavix): für wen Wie viel Wie lange Arznei-telegramm
2006;37:101-109.
153. Diener H et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or
transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled
trial. Lancet 2004;364:331-337.
154. Bogaert M. En prévention secondaire, ajouter de l’aspirine au clopidogrel Minerva 2005;4:87-89.
155. Bhatt D, Fox K, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of
atherothrombotic events. N Engl J Med 2006;354:1706-1717.
156. P Chevalier. Pas d’intérêt de rajouter du clopidogrel à l’aspirine en prévention cardiovasculaire. Minerva
2006;5:88-91.
157. Leonardi-Bee J, Bath P, Bousser M-G et al. Dipyridamole for preventing recurrent ischemic stroka and
other vascular events. Stroke 2005;36:162-168.
158. The ESPRIT Study Group. Aspirin plus diprydamole versus aspirin alone after cerebral ischaemia of
arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673.
159. Fiche de transparence ‘Prévention secondaire des accidents vasculaires cérébraux’ Mai 2007.
www.cbip.be
160. Norrving B. Dipyridamole with aspirin for secondary stroke prevention. Lancet 2006;367:1638-1639.
161. P Chevalier. Associer du dipyridamole à l’aspirine post événement ischémique cérébral Minerva
2006;5:114-116.
162. Wiersma T. Addendum bij de NHG-Standaard TIA: voortaan ook dipyridamol. Huisarts Wet
2006;49:671.
163. Traitement médicamenteux de la démence. Centre Belge d’Information Pharmacothérapeutique. Fiche
de transparence 2003. www.cbip.be
164. Anonymous. Qui a dit que le Nootropil ® (piracétam) n’avait pas d’action La Lettre du Gras 2002;35:41.
38 Système cardiovasculaire